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Abstract
Background: Huntington's disease (HD) is a fully penetrant, autosomal dominantly inherited
disorder associated with abnormal expansions of a stretch of perfect CAG repeats in the 5' part of
the IT15 gene. The number of repeat units is highly predictive for the age at onset (AO) of the
disorder. But AO is only modestly correlated with repeat length when intermediate HD
expansions are considered. Circumstantial evidence suggests that additional features of the HD
course are based on genetic traits. Therefore, it may be possible to investigate the genetic
background of HD, i.e. to map the loci underlying the development and progression of the disease.
Recently an association of Glutathione S-Transferase Ω 1 (GSTO1) and possibly of GSTO2 with AO
was demonstrated for, both, Alzheimer's (AD) and Parkinson's disease (PD).
Methods: We have genotyped the polymorphisms rs4925 GSTO1 and rs2297235 GSTO2 in 232
patients with HD and 228 controls.
Results: After genotyping GSTO1 and GSTO2 polymorphisms, firstly there was no statistically
significant difference in AO for HD patients, as well as secondly for HD patients vs. controls
concerning, both, genotype and allele frequencies, respectively.
Conclusion: The GSTO1 and GSTO2 genes flanked by the investigated polymorphisms are not
comprised in a primary candidate region influencing AO in HD.
Background
HD is an autosomal dominantly transmitted, progressive,
neurodegenerative disorder that is associated with an
expanded block of CAG repeats in exon 1 of the IT15 gene
(chromosome 4p) which encodes the protein huntingtin.
The CAG repeat mutation is translated into an abnormally
long polyglutamine tract, which is believed to acquire a
deleterious gain of function in the mutant protein. How-
ever, though variation in repeat length may explain some
of the variation in AO and, together with the observed
progression of expansion over generations, it provides a
molecular basis for the phenomenon of anticipation,
other variables play a role, particularly in those cases
where pathological CAG repeat numbers range in the high
30s or low 40s [1]. This insight has prompted the search
for additional genes influencing AO in HD. Defining such
independent predisposition factors is of paramount
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importance, since they may provide further clues pertain-
ing to the pathology arising from the expanded repeats.
Recent association studies showed that single nucleotide
polymorphisms (SNP) in the GSTO1 and GSTO2 gene
region are associated with AO in AD and PD, rendering
this region a likely candidate to affect AO in other neuro-
degenerative diseases, too [2]. The GSTs belong to a family
of enzymes that utilize glutathione in reactions contribut-
ing to the transformation of a wide range of exogenous
and endogenous compounds, including drugs, carcino-
gens, and the products of oxidative stress [OMIM 60548].
Therefore, the GSTO1 and GSTO2 genotypes were deter-
mined for HD patients that had previously been analysed
with respect to CAG repeat length.
Methods
232 patients with clinical diagnosis of HD were recruited
from the Huntington Center (HZ) NRW. Clinical assess-
ment and determination of AO was performed exclusively
by experienced neurologists/psychiatrists of the HZ NRW.
The motor AO was ascertained by the clinical specialists
for 143 patients. Controls (healthy blood donors from the
German populations of Essen and Hamburg) were also
genotyped for comparison. All patients and controls had
given informed consent for genotyping.
CAG repeat sizes were determined after PCR amplification
of genomic DNA from peripheral white blood cells. CAG
repeats were amplified by established methods [3]. The
polymorphism Ala140Asp (rs4925) of the GSTO1 gene
was demonstrated after PCR amplification using the fol-
lowing primers: 5'-AAAGTTGTTTCTTAAACGTGCC-3'
and 5'-AAGTGACTTGGAAAGTGGGAA-3'. PCR was car-
ried out in a final volume of 20 µl with 50 ng of DNA, 200
µM dNTP and 0.25 U Taq Polymerase. Thermal cycling
was performed with an initial activation step at 95°C for
15 min; 35 cycles of denaturation at 94°C for 1 min,
annealing at 55°C for 1 min and extension at 72°C for 1
min; and a final extension at 72°C for 10 min. PCR prod-
ucts were digested with the restriction enzyme Cac8 I at
37°C overnight and visualised on 2% agarose gels stained
with ethidium bromide. This digestion reveals a bi-allelic
polymorphism with altogether 4 bands of different sizes:
a 388 bp fragment (together with a 67 bp band) corre-
sponding to the A allele (restriction site absent) as well as
a set of 243, 145 and 67 bp fragmenst corresponding to
the C allele (restriction sites present).
The transition polymorphism A to G (rs2297235) in the
GSTO2 gene was demonstrated using the following prim-
ers: 5'-TTACTTACCAAAGAGTGGCCAG-3' and 5'-CCG-
CAGGCTCCAGAAAC-3' under the same conditions
mentioned above. PCR products were digested with the
restriction enzyme Tsp509 I at 65°C overnight. The diges-
tion reveals a bi-allelic polymorphism with altogether 5
bands of different sizes: a 344 bp fragment specific for the
G allele (one restriction site absent) vs. a set of 282, 62, 52
and 5 bp corresponding to the A allele (restriction sites
present).
The variability in AO attributable to the CAG repeat
number was calculated by linear regression. For the regres-
sion analysis, we used the AO as the dependent variable,
and the size of the expanded CAG block, normal CAG
repeat, their interaction, and the rs4925 GSTO1 as well as
the rs2297235 GSTO2 genotypes as independent varia-
bles. SPSS, Ver.11.0 for Windows (SPSS Inc.), was used for
all statistical analyses.
Results and discussion
In the cohort with defined AO, the mean AO (±SD) was
47.61 (±8.7) years (range 25–73). The expanded CAG
repeat ranged from 41–45 (mean ± SD: 42.94 ± 1.2) and
the unexpanded repeat size ranged from 13–29 (mean ±
SD: 18.67 ± 2.8; one individual had a smaller allele carry-
ing 37 trinucleotides). As detailed in an earlier study con-
cerning the clinically thoroughly characterised HD cohort
[4], AO is negatively correlated with repeat lengths also in
the lower range of CAG expansions. The CAG repeat
length on normal chromosomes and the interaction failed
to show any association with the age of onset of HD
(Table 1). The expanded CAG repeat explained 27.7% of
the variance in AO. This relatively low value may be
explained by the small range of CAG repeats (41–45)
investigated. Adding the unexpanded CAG repeat and the
interaction term in the model did not affect the variance
of the AO variance explained (from 27.7 to 27.8%). With
respect to the small CAG repeat range the results are in
agreement with a recently published study which showed
a positive association with delayed AO of HD only for
expansions ≥ 47 CAG [5]. In order to increase statistical
power, further DNA samples of HD patients were
included in these GSTO  polymorphism studies. Both
SNPs in the GSTO region showed a virtually identical
association pattern due to the LD between these two. Nev-
ertheless, a rare haplotype (GSTO1 – GSTO2, ac-aa) was
more prevalent among HD patients compared to controls.
This difference was statistically insignificant. Thus all in
all, the distribution of the genotypes and allele frequen-
cies between HD and control subjects was not statistically
different (Table 2). Observed frequencies were in Hardy-
Weinberg equilibrium. Furthermore, the rs4925 GSTO1
and rs2297235 GSTO2 genotypes failed to show any asso-
ciation with the AO of HD (Table 1, Fig. 1 and Fig. 2).
The presence of insoluble protein aggregates within neu-
rons is a common hallmark of AD, PD and HD [6]. These
aggregates associated with the three neurodegenerative
disorders may represent a common final pathway byBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/7
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Table 1: Regression coefficients (SE) of the AO in dependence of the size of expanded CAG, normal CAG repeat, their interaction, and 
the rs4925 GSTO1 and rs2297235 GSTO2 genotypes
Regression coefficients (SE) P
Expanded CAG size -3.842 (0.522) <0.0001
Unexpanded CAG size -0.0228 (0.199) 0.909
Expanded* unexpanded CAG size -0.000527 (0.005) 0.909
rs4925 GSTO1 -0.841 (1.042) 0.421
rs2297235 GSTO2 -1.720 (1.042) 0.095
Table 2: Allele and genotype frequencies of the GSTO1 and GSTO2 variations in HD patients and controls
Patients (n = 232) Controls (n = 228)
Alleles (%) GSTO1/GSTO2 GSTO1/GSTO2
A/G 168 (36%)/151 (33%) 142 (31%)/134 (29%)
C/A 296 (64%)/313 (67%) 314 (69%)/322 (71%)
Genotypes
aa/gg 28 (12%)/24 (10.3%) 22 (10%)/20 (9%)
ac/ga 112 (48%)/103 (44.4%) 98 (43%)/94 (41%)
cc/aa 92 (40%)/105 (45.3%) 108 (47%)/114 (50%)
a and b. Relationship between GSTO genotypes and AO for 143 HD patients Figure 1
a and b. Relationship between GSTO genotypes and AO for 143 HD patients. For each genotype, the median AO is repre-
sented as black bar, the quartile is shown as solid box and the range is indicated by the margins. Differences are statistically 
insignificant.
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compromising the axonal transport through trapping of
molecules which are essential for cellular function such as
chaperons and the proteasomes [op. cit.] The AD-causing
mutations in the amyloid precursor protein (APP) render
valuable clues as to the mechanisms of the disease and
point to the relevance of amyloid β-protein (Aβ) toxicity
in sporadic AD. In addition, the highly penetrant muta-
tions of early-onset AD and PD implicate either Aβ or its
precursor, APP, and α-synuclein as a cause of the toxicity
and neuronal loss. The APOE*E4 as a risk factor for spo-
radic AD has contributed further to this understanding by
adding cholesterol and lipid metabolisms to the model
for Aβ toxicity [7]. As recently reported GSTO1 may be
involved in the activation of interleukin 1 (IL-1β), and
thus variation in GSTO1 could alter the efficacy of IL-1β
post-translational processing, modulating any inflamma-
tory response [8]. In particular, since IL-1β is induced by
Aβ peptide, our results suggest different modifying mech-
anisms for AO in HD in comparison to AD and PD, the
latter two entities being perhaps more closely related to
each other in this aspect. This assumption is further sub-
stantiated by findings which could not confirm the AO-
delaying effect of the ε4 allele of the ApoE genotype in HD
[9].
In conclusion, the rs4925 GSTO1 and rs2297235 GSTO2
genotypes failed to show any association with the AO of
HD. Furthermore, we found no evidence that the
expanded and unexpanded CAG repeats interact to influ-
ence the AO of HD in the range of 41–45 repeats.
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